HR+/HER2- Metastatic Breast Cancer: Future Directions in Care
Closing out their program on HR+/HER2- metastatic breast cancer, panelists look toward future evolutions in the treatment landscape.
Transcript:
Joyce A. O’Shaughnessy, MD: I’d like to thank you for being here today.… And I think…we want to front-load our endocrine therapy as much as we possibly can. We are going to get more and more tools to both understand mechanisms of resistance that are coming both at the tissue level and in the blood ctDNA [circulating tumor DNA] level and understand, I hope, with the help of you all there at Memorial [Sloan Kettering] and your tumor board, to understand the role of co-mutations and serial evolution of different clones coming up. And it’s going to be a lot of very important work over a lot of years to understand how to best help patients get the most durable benefit in endocrine therapy. Right now, we’re fortunate to be able to find PIK3CA mutations. Hopefully, soon, AKT mutations, PTEN loss. Or maybe we won’t even have to find those. We’ll be able to give capivasertib to everybody who’s progressing on CDK [inhibitors].… And then ESR1 mutations. It’s both good news but frustrating. Good news is it’s still an ER [estrogen receptor]-dependent breast cancer. Bad news is our traditional agents really don’t work well. But thankfully, we have a new agent that really can give the patient the opportunity to get a very durable response. About 25% of the patients going out about a year, 23%, I think, to be exact.… So we’ve got to find those ESR1 mutations. So thank you so much for your really thoughtful, comprehensive discussions and analysis. And I really want to thank our viewing audience as well and thank Targeted Oncology™ for putting together this tumor board so we can get together. I hope this is a valuable use of your time and, most importantly, that this will [provide] some practical application to your practice. Thank you all very much.
Transcript is AI-generated and edited for clarity and readability.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
